Dr. Petrylak on PSMA ADC for Patients with mCRPC

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

Petrylak says these patients were given 2.5 mg/kg of PSMA ADC for three weeks. This dose was found to be too high in some patients and was reduced to 2.3 mg/kg. Safety, tumor response by PSA, circulating tumor cells (CTC), imaging, biomarkers and clinical progression were assessed during the study.

The results of this phase II study showed that the patients who expressed PSMA on circulating tumor cells and had a lack of neuroendocrine markers responded to the antibody, Petrylak says. The drug was fairly well tolerated: only some instances of neutropenia and peripheral neuropathy were reported.

Petrylak says a second cohort of patients that are naïve to chemotherapy is undergoing analysis.